192 related articles for article (PubMed ID: 29769293)
1. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F; Florio T; Ferraù F; Kara E; Fanciulli G; Faggiano A; Colao A;
Endocr Relat Cancer; 2018 Sep; 25(9):R453-R466. PubMed ID: 29769293
[TBL] [Abstract][Full Text] [Related]
2. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
Ohmoto A; Morizane C
Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.
Abdel-Rahman O
Tumour Biol; 2014 Nov; 35(11):10615-25. PubMed ID: 25230786
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.
Lauricella E; Mandriani B; Cavallo F; Pezzicoli G; Chaoul N; Porta C; Cives M
Front Oncol; 2022; 12():957068. PubMed ID: 36059642
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
[No Abstract] [Full Text] [Related]
7. Surufatinib in neuroendocrine tumours.
Das M
Lancet Oncol; 2019 Apr; 20(4):e196. PubMed ID: 30880071
[No Abstract] [Full Text] [Related]
8. Update on multikinase inhibitor therapy for differentiated thyroid cancer.
Agrawal VR; Jodon G; Mushtaq R; Bowles DW
Drugs Today (Barc); 2018 Sep; 54(9):535-545. PubMed ID: 30303494
[TBL] [Abstract][Full Text] [Related]
9. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
12. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
Wiedenmann B; Pavel M; Kos-Kudla B
Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib for advanced pancreatic neuroendocrine tumors.
Hubner RA; Valle JW
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
16. Promising advances in the treatment of malignant pancreatic endocrine tumors.
Jensen RT; Delle Fave G
N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
[No Abstract] [Full Text] [Related]
17. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
18. The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms.
Zhang WH; Wang WQ; Gao HL; Yu XJ; Liu L
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188311. PubMed ID: 31442475
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Nelson MH; Dolder CR
Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
